Key facts
- This page summarizes Ph.D. Daniel Billen's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 May 2024, 16:14.
Ph.D. Daniel Billen - 21 May 2024 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- Director
- Issuer ticker
- AUPH
- Reported as of
- 21 May 2024
- Net transaction value
- -$30,146
- SEC form
- 4
- Accepted by SEC
- 22 May 2024, 16:14:25 UTC
- Prior SEC filing
- 23 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Billen, Ph.D.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ph.D. Daniel Billen filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 22 May 2024.
Change
- Previous filing in this sequence was filed on 23 May 2023.
- Current net transaction value: -$30,146.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Sale
- Transaction value
- $30,146
- Shares
- -5,252
- Change %
- -16%
- Price
- $5.74
- Shares after
- 28,141
- Date
- 21 May 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on May 19, 2023.